# Intapp, Inc.: financial statements, quarterly

INTA · Nasdaq · CIK 1565687 · [Technology](/sectors/technology.md) · fiscal year ends Jun 30

Pages: [Overview](/companies/inta.md) · [Financials](/companies/inta/financials.md) · [Filings](/companies/inta/filings.md) · [Insiders](/companies/inta/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/inta/financials.md?period=annual).

## Income statement

| Line item | Unit | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q4 FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [102](/filings/0000950170-24-123292.md) | [104](/filings/0000950170-25-013454.md) | [111](/filings/0000950170-25-064492.md) | [114 d](/filings/0001565687-26-000073.md) | [119](/filings/0001565687-25-000101.md) | [121](/filings/0001565687-26-000014.md) | [129](/filings/0001565687-26-000037.md) | [135 d](/filings/0001565687-26-000073.md) | [139](/filings/0001565687-25-000101.md) | [140](/filings/0001565687-26-000014.md) | [146](/filings/0001565687-26-000037.md) | [153 d](/filings/0001565687-26-000073.md) |
| Cost of revenue | $m | [31.6](/filings/0000950170-24-123292.md) | [30.8](/filings/0000950170-25-013454.md) | [30.6](/filings/0000950170-25-064492.md) | [30.7 d](/filings/0001565687-26-000073.md) | [31.9](/filings/0001565687-25-000101.md) | [32.5](/filings/0001565687-26-000014.md) | [32.7](/filings/0001565687-26-000037.md) | [34.1 d](/filings/0001565687-26-000073.md) | [35.2](/filings/0001565687-25-000101.md) | [35.1](/filings/0001565687-26-000014.md) | [35.5](/filings/0001565687-26-000037.md) | [34.2 d](/filings/0001565687-26-000073.md) |
| Gross profit | $m | [70.0](/filings/0000950170-24-123292.md) | [73.2](/filings/0000950170-25-013454.md) | [80.1](/filings/0000950170-25-064492.md) | [83.6 d](/filings/0001565687-26-000073.md) | [86.9](/filings/0001565687-25-000101.md) | [88.7](/filings/0001565687-26-000014.md) | [96.4](/filings/0001565687-26-000037.md) | [101 d](/filings/0001565687-26-000073.md) | [104](/filings/0001565687-25-000101.md) | [105](/filings/0001565687-26-000014.md) | [111](/filings/0001565687-26-000037.md) | [118 d](/filings/0001565687-26-000073.md) |
| Research and development | $m | [28.5](/filings/0000950170-24-123292.md) | [28.0](/filings/0000950170-25-013454.md) | [27.3](/filings/0000950170-25-064492.md) | [29.8 d](/filings/0001565687-26-000073.md) | [32.4](/filings/0001565687-25-000101.md) | [33.3](/filings/0001565687-26-000014.md) | [34.1](/filings/0001565687-26-000037.md) | [37.9 d](/filings/0001565687-26-000073.md) | [40.9](/filings/0001565687-25-000101.md) | [39.3](/filings/0001565687-26-000014.md) | [44.1](/filings/0001565687-26-000037.md) | [43.0 d](/filings/0001565687-26-000073.md) |
| Operating income | $m | [(14.0)](/filings/0000950170-24-123292.md) | [(11.1)](/filings/0000950170-25-013454.md) | [(7.4)](/filings/0000950170-25-064492.md) | [0.3 d](/filings/0001565687-26-000073.md) | [(7.3)](/filings/0001565687-25-000101.md) | [(10.2)](/filings/0001565687-26-000014.md) | [(5.7)](/filings/0001565687-26-000037.md) | [(4.2) d](/filings/0001565687-26-000073.md) | [(14.5)](/filings/0001565687-25-000101.md) | [(7.2)](/filings/0001565687-26-000014.md) | [(14.2)](/filings/0001565687-26-000037.md) | [(4.2) d](/filings/0001565687-26-000073.md) |
| Interest expense | $m | [0.0](/filings/0000950170-23-061113.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [0.4](/filings/0000950170-24-123292.md) | [0.2](/filings/0000950170-25-013454.md) | [0.2](/filings/0000950170-25-064492.md) | [1.3 d](/filings/0001565687-26-000073.md) | [0.7](/filings/0001565687-25-000101.md) | [(0.2)](/filings/0001565687-26-000014.md) | [0.6](/filings/0001565687-26-000037.md) | [0.9 d](/filings/0001565687-26-000073.md) | [1.0](/filings/0001565687-25-000101.md) | [0.7](/filings/0001565687-26-000014.md) | [1.1](/filings/0001565687-26-000037.md) | [1.4 d](/filings/0001565687-26-000073.md) |
| Net income | $m | [(15.3)](/filings/0000950170-24-123292.md) | [(9.2)](/filings/0000950170-25-013454.md) | [(6.9)](/filings/0000950170-25-064492.md) | [(0.6) d](/filings/0001565687-26-000073.md) | [(4.5)](/filings/0001565687-25-000101.md) | [(10.2)](/filings/0001565687-26-000014.md) | [(3.0)](/filings/0001565687-26-000037.md) | [(0.5) d](/filings/0001565687-26-000073.md) | [(14.4)](/filings/0001565687-25-000101.md) | [(5.9)](/filings/0001565687-26-000014.md) | [(15.5)](/filings/0001565687-26-000037.md) | [(5.5) d](/filings/0001565687-26-000073.md) |
| Diluted EPS | $ per share | [(0.22)](/filings/0000950170-24-123292.md) | [(0.13)](/filings/0000950170-25-013454.md) | [(0.09)](/filings/0000950170-25-064492.md) | not reported | [(0.06)](/filings/0001565687-25-000101.md) | [(0.13)](/filings/0001565687-26-000014.md) | [(0.04)](/filings/0001565687-26-000037.md) | not reported | [(0.18)](/filings/0001565687-25-000101.md) | [(0.07)](/filings/0001565687-26-000014.md) | [(0.20)](/filings/0001565687-26-000037.md) | not reported |
| Basic EPS | $ per share | [(0.22)](/filings/0000950170-24-123292.md) | [(0.13)](/filings/0000950170-25-013454.md) | [(0.09)](/filings/0000950170-25-064492.md) | not reported | [(0.06)](/filings/0001565687-25-000101.md) | [(0.13)](/filings/0001565687-26-000014.md) | [(0.04)](/filings/0001565687-26-000037.md) | not reported | [(0.18)](/filings/0001565687-25-000101.md) | [(0.07)](/filings/0001565687-26-000014.md) | [(0.20)](/filings/0001565687-26-000037.md) | not reported |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [142](/filings/0000950170-24-123292.md) | [166](/filings/0000950170-25-013454.md) | [187](/filings/0000950170-25-064492.md) | [208](/filings/0001565687-26-000073.md) | [254](/filings/0001565687-25-000101.md) | [286](/filings/0001565687-26-000014.md) | [323](/filings/0001565687-26-000037.md) | [313](/filings/0001565687-26-000073.md) | [273](/filings/0001565687-25-000101.md) | [191](/filings/0001565687-26-000014.md) | [147](/filings/0001565687-26-000037.md) | [163](/filings/0001565687-26-000073.md) |
| Current assets | $m | [247](/filings/0000950170-23-061113.md) | [284](/filings/0000950170-24-012786.md) | [308](/filings/0000950170-24-056956.md) | [343](/filings/0001193125-25-184080.md) | [357](/filings/0000950170-24-123292.md) | [417](/filings/0000950170-25-013454.md) | [433](/filings/0000950170-25-064492.md) | [456](/filings/0001565687-26-000073.md) | [384](/filings/0001565687-25-000101.md) | [359](/filings/0001565687-26-000014.md) | [276](/filings/0001565687-26-000037.md) | [315](/filings/0001565687-26-000073.md) |
| Total assets | $m | [618](/filings/0000950170-23-061113.md) | [654](/filings/0000950170-24-012786.md) | [684](/filings/0000950170-24-056956.md) | [733](/filings/0001193125-25-184080.md) | [742](/filings/0000950170-24-123292.md) | [801](/filings/0000950170-25-013454.md) | [814](/filings/0000950170-25-064492.md) | [894](/filings/0001565687-26-000073.md) | [823](/filings/0001565687-25-000101.md) | [795](/filings/0001565687-26-000014.md) | [709](/filings/0001565687-26-000037.md) | [754](/filings/0001565687-26-000073.md) |
| Current liabilities | $m | [244](/filings/0000950170-23-061113.md) | [259](/filings/0000950170-24-012786.md) | [271](/filings/0000950170-24-056956.md) | [301](/filings/0001193125-25-184080.md) | [273](/filings/0000950170-24-123292.md) | [306](/filings/0000950170-25-013454.md) | [297](/filings/0000950170-25-064492.md) | [350](/filings/0001565687-26-000073.md) | [311](/filings/0001565687-25-000101.md) | [359](/filings/0001565687-26-000014.md) | [361](/filings/0001565687-26-000037.md) | [406](/filings/0001565687-26-000073.md) |
| Total liabilities | $m | [271](/filings/0000950170-23-061113.md) | [282](/filings/0000950170-24-012786.md) | [298](/filings/0000950170-24-056956.md) | [330](/filings/0001193125-25-184080.md) | [300](/filings/0000950170-24-123292.md) | [332](/filings/0000950170-25-013454.md) | [321](/filings/0000950170-25-064492.md) | [374](/filings/0001565687-26-000073.md) | [337](/filings/0001565687-25-000101.md) | [385](/filings/0001565687-26-000014.md) | [389](/filings/0001565687-26-000037.md) | [436](/filings/0001565687-26-000073.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [347](/filings/0000950170-25-013454.md) | [372](/filings/0000950170-25-064492.md) | [386](/filings/0000950170-25-064492.md) | [403](/filings/0001565687-26-000073.md) | [442](/filings/0001565687-26-000014.md) | [468](/filings/0001565687-26-000037.md) | [492](/filings/0001565687-26-000037.md) | [520](/filings/0001565687-26-000073.md) | [486](/filings/0001565687-26-000014.md) | [410](/filings/0001565687-26-000037.md) | [320](/filings/0001565687-26-000037.md) | [318](/filings/0001565687-26-000073.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q4 FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [11.6](/filings/0000950170-24-123292.md) | [12.0 d](/filings/0000950170-25-013454.md) | [16.5 d](/filings/0000950170-25-064492.md) | [27.1 d](/filings/0001565687-26-000073.md) | [24.4](/filings/0001565687-25-000101.md) | [25.2 d](/filings/0001565687-26-000014.md) | [35.5 d](/filings/0001565687-26-000037.md) | [38.3 d](/filings/0001565687-26-000073.md) | [13.8](/filings/0001565687-25-000101.md) | [22.9 d](/filings/0001565687-26-000014.md) | [63.9 d](/filings/0001565687-26-000037.md) | [46.3 d](/filings/0001565687-26-000073.md) |
| Capital expenditure | $m | [1.1](/filings/0000950170-24-123292.md) | [0.2 d](/filings/0000950170-25-013454.md) | [0.4 d](/filings/0000950170-25-064492.md) | [0.7 d](/filings/0001565687-26-000073.md) | [0.4](/filings/0001565687-25-000101.md) | [0.1 d](/filings/0001565687-26-000014.md) | [0.4 d](/filings/0001565687-26-000037.md) | [0.9 d](/filings/0001565687-26-000073.md) | [0.6](/filings/0001565687-25-000101.md) | [0.7 d](/filings/0001565687-26-000014.md) | [0.6 d](/filings/0001565687-26-000037.md) | [0.4 d](/filings/0001565687-26-000073.md) |
| Share repurchases | $m | not reported | not reported | not reported | not reported | [0.0](/filings/0001565687-25-000101.md) | [0.0 d](/filings/0001565687-26-000014.md) | [0.0 d](/filings/0001565687-26-000037.md) | [0.0 d](/filings/0001565687-26-000073.md) | [50.0](/filings/0001565687-25-000101.md) | [100 d](/filings/0001565687-26-000014.md) | [100 d](/filings/0001565687-26-000037.md) | [25.0 d](/filings/0001565687-26-000073.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q1 FY2023 (2022-09-30) | Q2 FY2023 (2022-12-31) | Q3 FY2023 (2023-03-31) | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [62.9](/filings/0000950170-23-061113.md) | [63.3](/filings/0000950170-24-012786.md) | [64.3](/filings/0000950170-24-056956.md) | [68.9](/filings/0000950170-24-123292.md) | [70.5](/filings/0000950170-25-013454.md) | [72.6](/filings/0000950170-25-064492.md) | [75.6](/filings/0001565687-25-000101.md) | [78.1](/filings/0001565687-26-000014.md) | [79.9](/filings/0001565687-26-000037.md) | [81.9](/filings/0001565687-25-000101.md) | [81.0](/filings/0001565687-26-000014.md) | [78.9](/filings/0001565687-26-000037.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 76,511,148 at 2026-08-06, from the cover of the [10-K filed 2026-08-14](/filings/0001565687-26-000073.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:43 ET. No prices; not investment advice.